Prevalence, Patterns of Treatment, and Control of Hypertension in Predialysis Patients with Chronic Kidney Disease

Publisher： Karger

E-ISSN： 1660-2110|120|3|c147-c155

ISSN： 1660-2110

Source： Nephron Clin Pract, Vol.120, Iss.3, 2012-06, pp. : c147-c155

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cutaneuos findings in patients with predialysis chronic kidney disease

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 30, Iss. 9, 2016-09 ,pp. : 1609-1613

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia

By Papatheofanis Frank J.   McKenzie R. Scott   Mody Samir H.   Suruki Robert Y.   Piech Catherine Tak  

Current Medical Research and Opinion, Vol. 22, Iss. 5, 2006-05 ,pp. : 837-842

Informa Healthcare

Access to resources Recommend Favorite

Prevalence, determinants, and clinical significance of masked hypertension and white‐coat hypertension in patients with chronic kidney disease

By  

NEPHROLOGY, Vol. 21, Iss. 10, 2016-10 ,pp. : 841-850

John Wiley & Sons Inc

Access to resources Recommend Favorite

Proteinuria as a Risk Marker for the Progression of Chronic Kidney Disease in Patients on Predialysis Care and the Role of Angiotensin-Converting Enzyme Inhibitor/Angiotensin II Receptor Blocker Treatment

By  

Nephron Clin Pract, Vol. 121, Iss. 1-2, 2012-10 ,pp. : c73-c82

Karger

Access to resources Recommend Favorite

Treatment of renal anaemia with erythropoiesis‐stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis

By  

NEPHROLOGY, Vol. 20, Iss. S4, 2015-12 ,pp. : 29-32

John Wiley & Sons Inc

Access to resources Recommend Favorite